---
title: "Cellectis publishes corporate presentation on allogeneic CAR-T pipeline, TALEN gene-editing platform"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295217037.md"
description: "Cellectis published a corporate presentation detailing its allogeneic CAR-T pipeline, highlighting four ongoing clinical trials and its TALEN gene-editing platform. The company reported a cash position of USD 169 million as of June 30, 2026, with runway into Q4 2027. Key milestones include the first interim analysis for lasme-cel in Q4 2026 and full dataset for eti-cel by the same period. Manufacturing is centered in Paris and Raleigh."
datetime: "2026-08-07T10:16:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295217037.md)
  - [en](https://longbridge.com/en/news/295217037.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295217037.md)
generator: "portal-rs"
---

# Cellectis publishes corporate presentation on allogeneic CAR-T pipeline, TALEN gene-editing platform

-   Cellectis outlined 4 ongoing allogeneic CAR-T clinical trials, including 2 pivotal Phase 2 studies and 2 Phase 1 studies. \* Cash position of USD 169 million as of June 30, 2026; expected runway into Q4 2027. \* Lasme-cel pivotal Phase 2 first interim analysis expected in Q4 2026; eti-cel Phase 1 full dataset expected in Q4 2026. \* Presentation highlighted TALEN gene-editing platform positioning on safety, precision, efficiency, versatility. \* Manufacturing footprint centered on Paris, France, and Raleigh, North Carolina, supporting end-to-end in-house production. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CLLS.US](https://longbridge.com/en/quote/CLLS.US.md)

## Related News & Research

- [Cellectis expects interim readout in Q4 2026 from pivotal BALLI-01 trial of lasme-cel in relapsed/refractory B-cell ALL](https://longbridge.com/en/news/295149883.md)
- [Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft](https://longbridge.com/en/news/296352331.md)
- [Imugene shareholders back capital-raising resolutions at extraordinary meeting](https://longbridge.com/en/news/296287728.md)
- [ALLO: Allogeneic CAR T platform shows strong efficacy, safety, and broad market potential across key indications](https://longbridge.com/en/news/295718267.md)
- [Ecolab sets R$ 0.13 per unit distribution for Q3 2026, payable Oct. 21](https://longbridge.com/en/news/296635995.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**